Author:
Shah Neil P.,Kasap Corynn,Weier Christopher,Balbas Minna,Nicoll John M.,Bleickardt Eric,Nicaise Claude,Sawyers Charles L.
Subject
Cancer Research,Cell Biology,Oncology
Reference23 articles.
1. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer;Amann;Cancer Res.,2005
2. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate;Brave;Clin. Cancer Res.,2008
3. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas;Burris;J. Clin. Oncol.,2005
4. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases;Carter;Proc. Natl. Acad. Sci. USA,2005
5. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets;Cohen;Clin. Cancer Res.,2004
Cited by
205 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献